RNome in Cancer Therapy

  • Mansi Arora
  • Deepak Kaul


RNA is a versatile molecule that performs myriad roles in the cells. The differential expression of RNA is both indicative and causative for many pathological conditions, including cancer. Comprehensive studies over the past decade have been instrumental in highlighting the tissue-specific expression and dysregulation of ncRNA expression and function in cancers of different origins. While the miRNAs have been thoroughly studied and their targets verified, the contribution of other small and long ncRNAs in the field of cancer biology needs further exploration and validation. RNA-based therapeutics, though an exciting field, is still in its infancy, and there are many issues to be addressed before it reaches the clinics. In this chapter we will discuss the use of ncRNAs as diagnostic and prognostic biomarkers in different types of cancer. We further discuss their contribution to intrinsic and acquired chemoresistance of cancer cells and strategies for modulating the abundance and functions of both coding and non-coding RNAs in vivo. We also deliberate over the challenges and recent platforms for the delivery of therapeutic RNAs to the target site.


Cancer biomarkers Chemotherapy resistance Delivery systems Non-coding RNAs Therapeutic RNAs 


  1. Akerman ME, Chan WCW, Laakkonen P et al (2002) Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99:12617–12621. Scholar
  2. Albertazzi L, Mickler FM, Pavan GM et al (2012) Enhanced bioactivity of internally functionalized cationic dendrimers with PEG cores. Biomacromolecules 13:4089–4097. Scholar
  3. Alegre E, Sanmamed MF, Rodriguez C et al (2014) Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 138:828–832. Scholar
  4. André EM, Passirani C, Seijo B et al (2016) Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: application to Huntington’s disease. Biomaterials 83:347–362. Scholar
  5. Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008. Scholar
  6. Aryani A, Denecke B (2016) Exosomes as a nanodelivery system: a key to the future of neuromedicine? Mol Neurobiol 53:818–834. Scholar
  7. Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126. Scholar
  8. Bak RO, Mikkelsen JG (2014) miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 5:317–333. Scholar
  9. Bak RO, Hollensen AK, Primo MN et al (2013) Potent microRNA suppression by RNA Pol II-transcribed “Tough Decoy” inhibitors. RNA 19:280–293. Scholar
  10. Balazs DA, Godbey W (2011) Liposomes for use in gene delivery. J Drug Deliv 2011. Scholar
  11. Bao L, Hazari S, Mehra S et al (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503. Scholar
  12. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333. Scholar
  13. Bartlett DW, Davis ME (2007) Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 97:909–921. Scholar
  14. Bartlett DW, Su H, Hildebrandt IJ et al (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 104:15549–15554. Scholar
  15. Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14:1122–1132. Scholar
  16. Bennett MJ, Nantz MH, Balasubramaniam RP et al (1995) Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells. Biosci Rep 15:47–53CrossRefGoogle Scholar
  17. Berezhnoy A, Castro I, Levay A et al (2014) Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 124:188–197. Scholar
  18. Bernardo BC, Gao X-M, Winbanks CE et al (2012) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 109:17615–17620. Scholar
  19. Berrondo C, Flax J, Kucherov V et al (2016) Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One 11:e0147236. Scholar
  20. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472CrossRefGoogle Scholar
  21. Boden D, Pusch O, Lee F et al (2003) Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res 31:5033–5038CrossRefGoogle Scholar
  22. Broderick JA, Zamore PD (2011) MicroRNA therapeutics. Gene Ther 18:1104–1110. Scholar
  23. Brown BD, Gentner B, Cantore A et al (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25:1457–1467. Scholar
  24. Bryant RJ, Pawlowski T, Catto JWF et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. Scholar
  25. Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405. Scholar
  26. Campani V, Salzano G, Lusa S, De Rosa G (2016) Lipid nanovectors to deliver RNA oligonucleotides in cancer. Nanomaterials 6. Scholar
  27. Cazzoli R, Buttitta F, Di Nicola M et al (2013) microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8:1156–1162. Scholar
  28. Cerchia L, de Franciscis V (2010) Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28:517–525. Scholar
  29. Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer 140:1955–1967. Scholar
  30. Chen CY, Shyu AB (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20:465–470CrossRefGoogle Scholar
  31. Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006. Scholar
  32. Chen Y, Gao D-Y, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141. Scholar
  33. Cheng G (2015) Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 81:75–93. Scholar
  34. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254. Scholar
  35. Chitkara D, Singh S, Mittal A (2016) Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. Ther Deliv 7:245–255. Scholar
  36. Citti L, Rainaldi G (2005) Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther 5:11–24CrossRefGoogle Scholar
  37. Conry RM, LoBuglio AF, Wright M et al (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397–1400PubMedGoogle Scholar
  38. Costa PM, Cardoso AL, Custódia C et al (2015) MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J Control Release 207:31–39. Scholar
  39. Darfeuille F, Reigadas S, Hansen JB et al (2006) Aptamers targeted to an RNA hairpin show improved specificity compared to that of complementary oligonucleotides. Biochemistry (Mosc) 45:12076–12082. Scholar
  40. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668. Scholar
  41. Davis ME, Zuckerman JE, Choi CHJ et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070. Scholar
  42. Deras IL, Aubin SMJ, Blase A et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587–1592. Scholar
  43. Doench JG, Petersen CP, Sharp PA (2003) siRNAs can function as miRNAs. Genes Dev 17:438–442. Scholar
  44. Dong Y, Zhao J, Wu C-W et al (2013) Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res MCR 11:1051–1060. Scholar
  45. Donzelli S, Mori F, Biagioni F et al (2014) MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2:16. Scholar
  46. Du Y, Kong G, You X et al (2012) Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287:26302–26311. Scholar
  47. Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16:2043–2050. Scholar
  48. Eblen ST (2012) Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 83:1063–1072. Scholar
  49. Eichelser C, Stückrath I, Müller V et al (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5:9650–9663. Scholar
  50. El-Andaloussi S, Järver P, Johansson HJ, Langel U (2007) Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 407:285–292. Scholar
  51. Ernsting MJ, Murakami M, Roy A, Li S-D (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782–794. Scholar
  52. Esposito T, Magliocca S, Formicola D, Gianfrancesco F (2011) piR_015520 belongs to Piwi-associated RNAs regulates expression of the human melatonin receptor 1A gene. PLoS One 6:e22727. Scholar
  53. Forman JJ, Coller HA (2010) The code within the code: microRNAs target coding regions. Cell Cycle Georget Tex 9:1533–1541. Scholar
  54. Frampton AE, Castellano L, Colombo T et al (2014) MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 146:268–277.e18. Scholar
  55. Gentner B, Schira G, Giustacchini A et al (2009) Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6:63–66. Scholar
  56. Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77:311–319PubMedGoogle Scholar
  57. Gumireddy K, Young DD, Xiong X et al (2008) Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Eng 47:7482–7484. Scholar
  58. Gupta RA, Shah N, Wang KC et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076. Scholar
  59. Han Li C, Chen Y (2015) Small and long non-coding RNAs: novel targets in perspective cancer therapy. Curr Genomics 16:319–326. Scholar
  60. Hang Q, Sun R, Jiang C, Li Y (2015) Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drugs 26:632–640. Scholar
  61. Hanini A, Schmitt A, Kacem K et al (2011) Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine 6:787–794. Scholar
  62. Hanke M, Hoefig K, Merz H et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661. Scholar
  63. Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. Scholar
  64. Hao Z, Fan W, Hao J et al (2016) Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv 23:874–881. Scholar
  65. Harrington KJ, Lewanski C, Northcote AD et al (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer Oxf Engl 37:2015–2022CrossRefGoogle Scholar
  66. Heitz F, Morris MC, Divita G (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195–206. Scholar
  67. Hiraki M, Nishimura J, Takahashi H et al (2015) Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. Mol Ther Nucleic Acids 4:e231. Scholar
  68. Höbel S, Aigner A (2013) Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5:484–501. Scholar
  69. Holtkamp S, Kreiter S, Selmi A et al (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009–4017. Scholar
  70. Hope MJ (2014) Enhancing siRNA delivery by employing lipid nanoparticles. Ther Deliv 5:663–673. Scholar
  71. Hu QL, Jiang QY, Jin X et al (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34:2265–2276. Scholar
  72. Huang X, Yuan T, Liang M et al (2015) Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67:33–41. Scholar
  73. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315CrossRefGoogle Scholar
  74. Janssen HLA, Reesink HW, Lawitz EJ et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694. Scholar
  75. Jemielity J, Fowler T, Zuberek J et al (2003) Novel “anti-reverse” cap analogs with superior translational properties. RNA 9:1108–1122CrossRefGoogle Scholar
  76. Jiang M, Huang O, Xie Z et al (2014) A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 87:254–283. Scholar
  77. Johnston SR, Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer Oxf Engl 1990(37 Suppl 9):S8–S14CrossRefGoogle Scholar
  78. Judge A, MacLachlan I (2008) Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19:111–124. Scholar
  79. Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36:4158–4171. Scholar
  80. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S et al (2011) Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 46:1391–1402. Scholar
  81. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012) Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther J Am Soc Gene Ther 20:513–524. Scholar
  82. Kawakami S, Yamashita F, Nishikawa M et al (1998) Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun 252:78–83. Scholar
  83. Kawamata T, Seitz H, Tomari Y (2009) Structural determinants of miRNAs for RISC loading and slicer-independent unwinding. Nat Struct Mol Biol 16:953–960. Scholar
  84. Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 31:700–707CrossRefGoogle Scholar
  85. Keklikoglou I, Hosaka K, Bender C et al (2015) MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene 34:4867–4878. Scholar
  86. Khatri N, Rathi M, Baradia D et al (2012) In vivo delivery aspects of miRNA, shRNA and siRNA. Crit Rev Ther Drug Carrier Syst 29:487–527CrossRefGoogle Scholar
  87. Khvorova A, Lescoute A, Westhof E, Jayasena SD (2003) Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat Struct Biol 10:708–712. Scholar
  88. Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 44:853–862. Scholar
  89. Kievit FM, Veiseh O, Bhattarai N et al (2009) PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 19:2244–2251. Scholar
  90. Kim J-K, Choi S-H, Kim C-O et al (2003) Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J Pharm Pharmacol 55:453–460. Scholar
  91. Kim C, Shah BP, Subramaniam P, Lee K-B (2011) Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Mol Pharm 8:1955–1961. Scholar
  92. Koga Y, Yasunaga M, Takahashi A et al (2010) MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 3:1435–1442. Scholar
  93. Kolb G, Reigadas S, Castanotto D et al (2006) Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication. RNA Biol 3:150–156CrossRefGoogle Scholar
  94. Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140. Scholar
  95. Kosaka N, Izumi H, Sekine K, Ochiya T (2010) microRNA as a new immune-regulatory agent in breast milk. Silence 1:7. Scholar
  96. Kuhn AN, Diken M, Kreiter S et al (2010) Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17:961–971. Scholar
  97. Kuhn AN, Beiβert T, Simon P et al (2012) mRNA as a versatile tool for exogenous protein expression. Curr Gene Ther 12:347–361CrossRefGoogle Scholar
  98. Kundu SK, Sharma AR, Lee S-S et al (2014) Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int 2014. Scholar
  99. Lee SH, Castagner B, Leroux J-C (2013) Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV 85:5–11. Scholar
  100. Lee B, Mazar J, Aftab MN et al (2014) Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn 16:615–626. Scholar
  101. Lewis H, Lance R, Troyer D et al (2014) miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle Georget Tex 13:227–239. Scholar
  102. Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:622–638. Scholar
  103. Ling H, Girnita L, Buda O, Calin GA (2017) Non-coding RNAs: the cancer genome dark matter that matters! Clin Chem Lab Med 55:705–714. Scholar
  104. Link A, Becker V, Goel A et al (2012) Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One 7:e42933. Scholar
  105. Liu Y, Wang J (2016) Therapeutic potentials of noncoding RNAs: targeted delivery of ncRNAs in cancer cells. Adv Exp Med Biol 927:429–458. Scholar
  106. Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055–4060PubMedGoogle Scholar
  107. Liu J, Sun H, Wang X et al (2014) Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci 15:758–773. Scholar
  108. Lünse CE, Michlewski G, Hopp CS et al (2010) An aptamer targeting the apical-loop domain modulates pri-miRNA processing. Angew Chem Int Ed Eng 49:4674–4677. Scholar
  109. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029–4033PubMedGoogle Scholar
  110. Ma Y, Yang Y, Wang F et al (2016) Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut 65:1494–1504. Scholar
  111. Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M (2011) Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell “vision” versus physicochemical properties of nanoparticles. ACS Nano 5:7263–7276. Scholar
  112. Mallick S, Choi JS (2014) Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J Nanosci Nanotechnol 14:755–765CrossRefGoogle Scholar
  113. Manterola L, Guruceaga E, Gállego Pérez-Larraya J et al (2014) A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncol 16:520–527. Scholar
  114. Martin SA, Paoletti E, Moss B (1975) Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem 250:9322–9329PubMedGoogle Scholar
  115. Mayer G, Raddatz M-SL, Grunwald JD, Famulok M (2007) RNA ligands that distinguish metabolite-induced conformations in the TPP riboswitch. Angew Chem Int Ed Eng 46:557–560. Scholar
  116. McClorey G, Wood MJ (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 24:52–58. Scholar
  117. Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544–550CrossRefGoogle Scholar
  118. Metselaar JM, Bruin P, de Boer LWT et al (2003) A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156–1164. Scholar
  119. Migault M, Donnou-Fournet E, Galibert M-D, Gilot D (2017) Definition and identification of small RNA sponges: focus on miRNA sequestration. Methods 117:35–47. Scholar
  120. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518. Scholar
  121. Mlcochova H, Hezova R, Stanik M, Slaby O (2014) Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 32:41.e1–41.e9. Scholar
  122. Mulhbacher J, St-Pierre P, Lafontaine DA (2010) Therapeutic applications of ribozymes and riboswitches. Curr Opin Pharmacol 10:551–556. Scholar
  123. Nchinda G, Uberla K, Zschörnig O (2002) Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition. BMC Biotechnol 2:12CrossRefGoogle Scholar
  124. O’Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318–328CrossRefGoogle Scholar
  125. Obad S, dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371–378. Scholar
  126. Ochiya T, Takahama Y, Nagahara S et al (1999) New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 5:707–710. Scholar
  127. Ochiya T, Nagahara S, Sano A et al (2001) Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 1:31–52CrossRefGoogle Scholar
  128. Ogata-Kawata H, Izumiya M, Kurioka D et al (2014) Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 9:e92921. Scholar
  129. Otaegi G, Pollock A, Sun T (2011) An optimized sponge for microRNA miR-9 affects spinal motor neuron development in vivo. Front Neurosci 5:146. Scholar
  130. Park NJ, Zhou H, Elashoff D et al (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res Off J Am Assoc Cancer Res 15:5473–5477. Scholar
  131. Patil ML, Zhang M, Betigeri S et al (2008) Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 19:1396–1403. Scholar
  132. Patil ML, Zhang M, Taratula O et al (2009) Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 10:258–266. Scholar
  133. Peer D, Zhu P, Carman CV et al (2007) Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 104:4095–4100. Scholar
  134. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CMP (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18:282–289. Scholar
  135. Petersen M, Wengel J (2003) LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 21:74–81. Scholar
  136. Petersen KE, Manangon E, Hood JL et al (2014) A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. Anal Bioanal Chem 406:7855–7866. Scholar
  137. Pickard MR, Williams GT (2014) Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res Treat 145:359–370. Scholar
  138. Poliseno L, Salmena L, Zhang J et al (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033–1038. Scholar
  139. Pramanik D, Campbell NR, Karikari C et al (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10:1470–1480. Scholar
  140. Que R, Ding G, Chen J, Cao L (2013) Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol 11:219. Scholar
  141. Raal FJ, Santos RD, Blom DJ et al (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998–1006. Scholar
  142. Raza U, Zhang JD, Sahin O (2014) MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med Berl Ger 92:321–336. Scholar
  143. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Xu G, Liu Z, Hou J, Huang J, Sun Y (2013) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 49(13):2949–2959CrossRefGoogle Scholar
  144. Rivas A, Burzio V, Landerer E et al (2012) Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer. BMC Urol 12:37. Scholar
  145. Rothschild SI (2014) microRNA therapies in cancer. Mol Cell Ther 2:7. Scholar
  146. Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. Scholar
  147. Sarkar FH, Li Y, Wang Z et al (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 13:57–66. Scholar
  148. Schmidinger M, Wenzel C, Locker GJ et al (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850–1852. Scholar
  149. Schwarzenbach H (2015) The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn 15:1159–1169. Scholar
  150. Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11:145–156. Scholar
  151. Scognamiglio I, Di Martino MT, Campani V, et al (2014) Transferrin-conjugated SNALPs encapsulating 2’-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int 2014:217365. doi: Scholar
  152. Scott WG (2007) Ribozymes. Curr Opin Struct Biol 17:280–286. Scholar
  153. Semple SC, Klimuk SK, Harasym TO et al (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510:152–166CrossRefGoogle Scholar
  154. Semple SC, Akinc A, Chen J et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172–176. Scholar
  155. Shen T, Han M, Wei G, Ni T (2015) An intriguing RNA species--perspectives of circularized RNA. Protein Cell 6:871–880. Scholar
  156. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6:267–283. Scholar
  157. Singha K, Namgung R, Kim WJ (2011) Polymers in small-interfering RNA delivery. Nucleic Acid Ther 21:133–147. Scholar
  158. Sitharaman B (2016) Nanobiomaterials handbook. CRC Press, Boca RatonGoogle Scholar
  159. Snead NM, Rossi JJ (2010) Biogenesis and function of endogenous and exogenous siRNAs. Wiley Interdiscip Rev RNA 1:117–131. Scholar
  160. Snøve O, Holen T (2004) Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 319:256–263. Scholar
  161. Song E, Zhu P, Lee S-K et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709–717. Scholar
  162. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–178. Scholar
  163. Srinageshwar B, Peruzzaro S, Andrews M et al (2017) PAMAM dendrimers cross the blood-brain barrier when administered through the carotid artery in C57BL/6J mice. Int J Mol Sci 18. Scholar
  164. Stanton R, Sciabola S, Salatto C et al (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther 22:344–359. Scholar
  165. Stepinski J, Waddell C, Stolarski R et al (2001) Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3’-O-methyl)GpppG and 7-methyl (3’-deoxy)GpppG. RNA 7:1486–1495PubMedPubMedCentralGoogle Scholar
  166. Subramanian N, Kanwar JR, Kanwar RK, Krishnakumar S (2015) Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma. Nucleic Acid Ther 25:47–52. Scholar
  167. Sugimachi K, Matsumura T, Hirata H et al (2015) Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 112:532–538. Scholar
  168. Sullenger BA, Nair S (2016) From the RNA world to the clinic. Science 352:1417–1420. Scholar
  169. Sun Z, Song X, Li X et al (2014) In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale 6:14343–14353. Scholar
  170. Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–9680. Scholar
  171. Tanaka Y, Kamohara H, Kinoshita K et al (2013) Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119:1159–1167. Scholar
  172. Tang Y, Li Y-B, Wang B, Lin R-Y, van Dongen M, Zurcher DM, Gu X-Y, Holl MMB, Liu G, Qi R (2012) Efficient siRNA delivery and intramuscular gene silencing using PEG-Modified PAMAM dendrimers. Mol Pharm 9(6):1812–1821CrossRefGoogle Scholar
  173. Tang H, Wu Z, Zhang J, Su B (2013) Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 7:761–766. Scholar
  174. Tantai J, Hu D, Yang Y, Geng J (2015) Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol 8:7887–7895PubMedPubMedCentralGoogle Scholar
  175. Tay FC, Lim JK, Zhu H et al (2015) Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev 81:117–127. Scholar
  176. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21. Scholar
  177. Taylor DD, Shah S (2015) Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 87:3–10. Scholar
  178. Tedeschi L, Lande C, Cecchettini A, Citti L (2009) Hammerhead ribozymes in therapeutic target discovery and validation. Drug Discov Today 14:776–783. Scholar
  179. Terasawa K, Shimizu K, Tsujimoto G (2011) Synthetic pre-miRNA-based shRNA as potent RNAi triggers. J Nucleic Acids 2011:131579. Scholar
  180. Thiel KW, Hernandez LI, Dassie JP et al (2012) Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319–6337. Scholar
  181. Toloue MM, Ford LP (2011) Antibody targeted siRNA delivery. Methods Mol Biol 764:123–139. Scholar
  182. Tripathi V, Ellis JD, Shen Z et al (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39:925–938. Scholar
  183. Tsuchiya Y, Nakajima M, Takagi S et al (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66:9090–9098. Scholar
  184. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510CrossRefGoogle Scholar
  185. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B (2013) Circulating miRNAs: cell-cell communication function? Front Genet 4:119. Scholar
  186. Turturici G, Tinnirello R, Sconzo G, Geraci F (2014) Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Phys Cell Phys 306:C621–C633. Scholar
  187. Vaksman O, Tropé C, Davidson B, Reich R (2014) Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 35:2113–2120. Scholar
  188. Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. Scholar
  189. Vickers KC, Palmisano BT, Shoucri BM et al (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433. Scholar
  190. Wang X, Wang Y, Chen ZG, Shin DM (2009) Advances of cancer therapy by nanotechnology. Cancer Res Treat 41:1–11. Scholar
  191. Wang J, Chen Y, Chen B et al (2010a) Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine 5:861–866. Scholar
  192. Wang K, Zhang S, Weber J et al (2010b) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 38:7248–7259. Scholar
  193. Wang F, Li T, Zhang B et al (2013a) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434:688–694. Scholar
  194. Wang Y, Xu Z, Jiang J et al (2013b) Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 25:69–80. Scholar
  195. Wang F, Ren S, Chen R et al (2014a) Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget 5:11091–11102. Scholar
  196. Wang H, Hou L, Li A et al (2014b) Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014:864894. Scholar
  197. Wang J, Zhou Y, Lu J et al (2014c) Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol Northwood Lond Engl 31:148. Scholar
  198. Wang Y, Zhang D, Wu K et al (2014d) Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol 34:3182–3193. Scholar
  199. Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741. Scholar
  200. Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468CrossRefGoogle Scholar
  201. Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149–1157. Scholar
  202. Wollina U, Dummer R, Brockmeyer NH et al (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001. Scholar
  203. Wu X, Yamamoto H, Nakanishi H et al (2015) Innovative delivery of siRNA to solid tumors by super carbonate apatite. PLoS One 10:e0116022. Scholar
  204. Xiao Z, Li CH, Chan SL et al (2014) A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res 74:6236–6247. Scholar
  205. Xie J, Huang J, Li X et al (2009) Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 16:1278–1294CrossRefGoogle Scholar
  206. Xie Z, Chen G, Zhang X et al (2013) Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 8:e57502. Scholar
  207. Xiong X-D, Ren X, Cai M-Y et al (2016) Long non-coding RNAs: an emerging powerhouse in the battle between life and death of tumor cells. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 26:28–42. Scholar
  208. Xue HY, Guo P, Wen W-C, Wong HL (2015) Lipid-based nanocarriers for RNA delivery. Curr Pharm Des 21:3140–3147CrossRefGoogle Scholar
  209. Yamada Y, Enokida H, Kojima S et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. Scholar
  210. Young DD, Connelly CM, Grohmann C, Deiters A (2010) Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 132:7976–7981. Scholar
  211. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284CrossRefGoogle Scholar
  212. Zelphati O, Szoka FC (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A 93:11493–11498CrossRefGoogle Scholar
  213. Zhang J-S, Liu F, Huang L (2005) Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57:689–698. Scholar
  214. Zhang Z, Hao H, Zhang C et al (2012) Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder cancer. Zhonghua Yi Xue Za Zhi 92:384–387PubMedGoogle Scholar
  215. Zhang Y, Wang Z, Gemeinhart RA (2013) Progress in microRNA delivery. J Control Release 172:962–974. Scholar
  216. Zhang W, Ren S-C, Shi X-L et al (2015) A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Prostate 75:653–661. Scholar
  217. Zhu H, Wu H, Liu X et al (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76:582–588. Scholar
  218. Ziemniak M, Strenkowska M, Kowalska J, Jemielity J (2013) Potential therapeutic applications of RNA cap analogs. Future Med Chem 5:1141–1172. Scholar
  219. Zinckgraf JW, Silbart LK (2003) Modulating gene expression using DNA vaccines with different 3’-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 21:1640–1649CrossRefGoogle Scholar
  220. Zuidam NJ, Barenholz Y (1998) Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta 1368:115–128CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Mansi Arora
    • 1
  • Deepak Kaul
    • 1
  1. 1.Department of Experimental Medicine and BiotechnologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations